AI is about to change healthcare. These 7 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
For Daikin, the big-picture belief is that efficient, low-carbon HVAC will keep gaining policy and customer support, and the company can translate its strong brand and balance sheet into resilient earnings. The launch of the EWYK-QZ heat pump in Europe fits neatly into that story, reinforcing Daikin’s positioning in a region where incentives and regulation are pushing toward greener heating. In the near term, the main catalysts still sit around execution versus guidance, the very large buyback, and how consistently Daikin can convert its sales base into profit, given its currently modest net margin and low return on equity. The EWYK-QZ itself is unlikely to drive an immediate step change, but it does slightly tilt the risk balance toward higher R&D and regulatory exposure in Europe.
However, investors also need to think about legal and pricing risks that could pressure returns. Despite retreating, Daikin IndustriesLtd's shares might still be trading 19% above their fair value. Discover the potential downside here.Explore 3 other fair value estimates on Daikin IndustriesLtd - why the stock might be worth as much as 24% more than the current price!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com